Observation of the curative effect of Sorafenib combined stereotactic body radiation therapy in the treatment of primary hepatocellular carcinoma with pulmonary metastasis
10.12025/j.issn.1008-6358.2016.20160309
- VernacularTitle:索拉非尼联合立体定向精确放疗治疗肝癌肺转移疗效观察
- Author:
Xiao-Lan YIN
1
;
Qing XU
Author Information
1. 同济大学医学院
- Keywords:
stereotactic body radiation therapy;
Sorafenib;
primary hepatocellular carcinoma;
pulmonary metastasis;
combined treatment
- From:
Chinese Journal of Clinical Medicine
2016;23(5):618-624
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the curative effect and adverse reaction of Sorafenib combined stereotactic body radiation therapy (SBRT)in the treatment of primary hepatocellular carcinoma (HCC)with pulmonary metastasis,and to evaluate the safety of combine treatment.Methods:Sixty primary HCC patients with pulmonary metastasis were recruited from June 2011 to June 2013.The patients were equally divided into combine treatment group,which received Sorafenib combined SBRT treatment and control group with only SBRT treatment.The curative effect,adverse reaction after three months of treatment,and long-term curative effect (1 year,2 years survival rate and median survival time)were compared between two groups.Results:After a three months of follow-up,the total efficiency rate of combined treatment group was 80.2%,which was significantly higher than control group of 73.3%(P= 0.045).The median time to progression in combined treatment group was 8.5 months,and control group was 4.6 months (P= 0.02).The one year survival rate in combined treatment was 53.3%(16/30),two year survival rate was 30%(9/30);and in control group,one year survival rate was 46.7%(14/30),two year survival rate was 20%(6/30).The median survival time of combined treatment group was 13.2 months,and that of control group was 11.8 months(P= 0.019).The toxicity in the two groups was tolerated,and no serious adverse reactions occurred.Conclusions:The Sorafenib combined with SBRT can improve the time to progression and median survival time of HCC patients with pulmonary metastasis without increasing the incidences of adverse events.
